First-line use of lung cancer drug Zykadia gets NHS nod

25th January 2018 Uncategorised 0

Final guidelines have now been published endorsing NHS use of Novartis’ Zykadia as a first line of attack for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), offering patients a new treatment option.

More: First-line use of lung cancer drug Zykadia gets NHS nod
Source: News